Table 5.

microRNAs modulated by histone deacetylase inhibitors used in cancer models.

Cancers	HDACi	miRNAs	miRNA Targets	Pathways	Ref.
Breast	LAQ824	miR27a (≈40% of miRNAs modulated)	RYBP/DEDAF, ZBTB10/RINZF		[101]
	TSA	22 miR among which: miR-1, miR-143, miR-144, miR-191-3p, miR-202-5p…	(predicted targets for each miRNAs provided in the article)		[132]
		10 miR among which: miR-500, miR-645, miR-512-3p, miR-613…
		(see article for complete listing)
	TSA, VPA NaBu…	miR125-a	HDAC5 mRNA	apoptosis	[133]
CCA	CG200746	miR-22-3p, miR-22-5p, miR-194-3p, miR-194-5p, miR-210-3p, miR-509-3p	expression induced in treated cells	tumor growth proliferation	[134]
Colorectal	PBA	miR-9, miR-127, miR-129, miR-137			[135]
	Butyrate	18 miRNAs	p21 protein expression	proliferation	[127]
		26 miRNAs (among which miR-17-92a, miR-18b-106 and miR25-106b clusters)
	Entinostat (MS-275)	pri and mature miR-21			[136]
Gastric carcinoma	TSA	miR-375	PDK1, XIAP, 14-3-3ζ (YWHAZ), cIAP-2 (BIRC3)	Tumor cell viability	[137]
			BCL2L11 (Bim)	apoptosis
HCC	TSA	miR-449	c-MET	cell proliferation apoptosis	[138]
	Sodium valproate	miR-889	MICB	sensitivity to NK cell-mediated lysis	[139]
Leukemia	valpromide (=VPA analog)	miR-144, miR-451, miR-155 (all cells)	GATA-1	erythropoiesis impairment	[140]
			GATA-2
		miR-15a, miR-16, miR-222 (some cells)	ETS family (PU.1, ETS-1, GABP-α, Fli-1)	megakaryocyte features
Lung	Entinostat (MS275)	miR-200a	KEAP1/NRF2	cell growth	[128]
	TSA	Let-7, miR-15a, miR-16-1		proliferation and apoptosis	[125]
				induce cell cycle arrest
Lymphoma	RGFP966	miR-15a, miR-195, let-7a (in vitro and in vivo)	BCL-2, BCL-XL	apoptosis	[126]
Melanoma	4PBA (or 5Aza, 5Aza + 4PBS)	miR-34b, miR-132, miR-142-3p, miR-200a, miR-375, miR-489		Proliferation, invasion	[141]
				wound healing
				changes in cell morphology
Multiple Myeloma	AR-42	miR-9-5p	CD44		[142]
Ovarian	AR42	miR-15a, miR-34, … (see figure in article)	WT1, PAX2, GATA6, APO2/TRAIL… (see article)	EMT, Canonical Wnt R signaling Negative regulation of cell cycle processes, extrinsic apoptosis	[104]
Pancreatic	AR-42	miR-30d, miR-33, miR-125b	p53, cyclin B2, CDC25B	Invasion, tumor growth	[129]
Prostate	Mocetinostat	miR-31	E2F6	apoptosis	[130]
	OBP-801	miR-320a in vitro and in vivo (rat)	PSA, androgen receptor	Viability, cell growth, cell proliferation, prostate tumorigenesis (in vivo)	[131]
Tongue	TSA (or Doxorubicin, 5-fluorouracil, etoposide treatments)	miR-375	CIP2A, MYC, 14-3-3z, E6AP, E6, E7	cell proliferation, migration and invasion	[143]
			p21, p53, RB
Various models	PBA (and 5-Aza-CdR)	17 miR/313 studied (see article for details)	BCL6 (suggested)		[144]
	TSA	miR132/212	MeCP2		[145]

NaBu, Sodium Butyrate, E2F: E2F transcription factor, p21/CIP1: cyclin-dependent kinase inhibitor 1A, MET: MET proto-oncogene, receptor tyrosine kinase, BCL-2: B-cell CLL/lymphoma 2, RYBP/DEDAF: RING1 and YY1 binding protein, ZBTB10/RINZF: zinc finger and BTB domain containing 10, HDAC5: histone deacetylase 5, PDK1: pyruvate dehydrogenase kinase, isozyme 1, XIAP: X-linked inhibitor of apoptosis, 14-3-3ζ (YWHAZ): tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta, cIAP-2 (BIRC3): baculoviral IAP repeat containing 3, BCL2L11 (Bim): BCL2-like 11, MICB: MHC class I polypeptide-related sequence B, GATA: globin transcription factor, KEAP1/NRF2: kelch-like ECH-associated protein 1, BCL-XL: BCL2-like 1, WT1: Wilms tumor 1, PAX2: paired box 2, APO2/TRAIL: tumor necrosis factor receptor superfamily, member 10a, PU.1: Spi-1 proto-oncogene, ETS-1: v-ets avian erythroblastosis virus E26 oncogene homolog 1, GABP-α: GA binding protein transcription factor, alpha subunit 60kDa, CDC25B: cell division cycle 25B, PSA: prostate specific antigen, CIP2A: cancerous inhibitor of PP2A, RB: retinoblastoma 1, BCL6: B-cell CLL/lymphoma 6, MeCP2: methyl CpG binding protein 2. Arrows indicate decrease () or increase () of either miRNA or target and their associated pathway.